open access

Vol 20, No 5 (2015)
Original reearch articles
Published online: 2015-09-01
Submitted: 2014-10-20
Get Citation

SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre, cross-sectional study

Pilar M Samper Ots, Julia Luisa Muñoz García, Yesika Ríos Kavadoy, M Luz Couselo Paniagua, Elena Villafranca Iturre, Milagrosa Rodríguez Liñán, Ana María Pérez Casas, Rodrigo Muelas Soria, Blanca Ludeña Martínez, José López Torrecilla, Manuel Casaña Giner, Almudena Zapatero Laborda, M Magdalena García-Salazar
DOI: 10.1016/j.rpor.2015.06.004
·
Rep Pract Oncol Radiother 2015;20(5):370-376.

open access

Vol 20, No 5 (2015)
Original reearch articles
Published online: 2015-09-01
Submitted: 2014-10-20

Abstract

Aim

To assess the prevalence of metabolic syndrome (MetS) and osteoporosis in patients with prostate cancer (PCa) treated with radical radiotherapy (RT) with or without androgen deprivation therapy (ADT).

Background

Worldwide, the prevalence of MetS is estimated to range from 20% to 25% of the adult population. However, prevalence rates are much higher in PCa patients (pts) who undergo ADT.

Materials and methods

Multicentre cross-sectional study of 270 pts in Spain with PCa. Patients were divided into 3 groups based on the duration of ADT (6, 12–18, ≥24 months) and compared to a control group without ADT. MetS was defined according to NCEP ATP III criteria. Osteoporosis was assessed by DEXA.

Results

A total of 270 pts, treated from November 2011 to October 2012, were included. Of these, 122 pts (47%) fulfilled the criteria for MetS. The median age of this group was significantly higher (71.3 vs. 69.38 years, p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.028). MetS prevalence was 50% in the control group. In pts who received ADT, prevalence was 44.8% after 6 months of ADT, 45.3% after 12–18 months, and 50% after ≥24 months (pns). Most pts (168/270; 62%) underwent DEXA. Of those tested, 78 (46.4%) had osteopenia and only 11 (6.5%) had osteoporosis.

Conclusions

The prevalence of MetS in pts with PCa treated with radical RT was higher (47%) than in the general population. However, there were no significant differences in the duration of ADT administration. The prevalence of osteoporosis was low. These findings suggest that the prevalence of MetS in PCa patients may be higher than previously reported.

Abstract

Aim

To assess the prevalence of metabolic syndrome (MetS) and osteoporosis in patients with prostate cancer (PCa) treated with radical radiotherapy (RT) with or without androgen deprivation therapy (ADT).

Background

Worldwide, the prevalence of MetS is estimated to range from 20% to 25% of the adult population. However, prevalence rates are much higher in PCa patients (pts) who undergo ADT.

Materials and methods

Multicentre cross-sectional study of 270 pts in Spain with PCa. Patients were divided into 3 groups based on the duration of ADT (6, 12–18, ≥24 months) and compared to a control group without ADT. MetS was defined according to NCEP ATP III criteria. Osteoporosis was assessed by DEXA.

Results

A total of 270 pts, treated from November 2011 to October 2012, were included. Of these, 122 pts (47%) fulfilled the criteria for MetS. The median age of this group was significantly higher (71.3 vs. 69.38 years, p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.028). MetS prevalence was 50% in the control group. In pts who received ADT, prevalence was 44.8% after 6 months of ADT, 45.3% after 12–18 months, and 50% after ≥24 months (pns). Most pts (168/270; 62%) underwent DEXA. Of those tested, 78 (46.4%) had osteopenia and only 11 (6.5%) had osteoporosis.

Conclusions

The prevalence of MetS in pts with PCa treated with radical RT was higher (47%) than in the general population. However, there were no significant differences in the duration of ADT administration. The prevalence of osteoporosis was low. These findings suggest that the prevalence of MetS in PCa patients may be higher than previously reported.

Get Citation

Keywords

Metabolic syndrome; Prostate cancer; Osteoporosis; Androgen deprivation therapy

About this article
Title

SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre, cross-sectional study

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 20, No 5 (2015)

Pages

370-376

Published online

2015-09-01

DOI

10.1016/j.rpor.2015.06.004

Bibliographic record

Rep Pract Oncol Radiother 2015;20(5):370-376.

Keywords

Metabolic syndrome
Prostate cancer
Osteoporosis
Androgen deprivation therapy

Authors

Pilar M Samper Ots
Julia Luisa Muñoz García
Yesika Ríos Kavadoy
M Luz Couselo Paniagua
Elena Villafranca Iturre
Milagrosa Rodríguez Liñán
Ana María Pérez Casas
Rodrigo Muelas Soria
Blanca Ludeña Martínez
José López Torrecilla
Manuel Casaña Giner
Almudena Zapatero Laborda
M Magdalena García-Salazar

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl